Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 8/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.66 |
| ▸ | THRB | P10828 | 7/20 | 0.66 |
| ▸ | BLM | P54132 | 7/20 | 0.66 |
| ▸ | RECQL | P46063 | 6/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | STAT6 | P42226 | 4/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL19876659 | 1.00 | MEN1 (0.66) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL4020691 | 0.99 | MEN1 (0.67) | MEN1KMT2ATHRBBLMRECQL | |
| Daunorubicin SCHEMBL3503884 | 0.95 | MEN1 (0.65) | MEN1KMT2ATHRBBLMRECQL | |
| Zorubicin SCHEMBL168293 | 0.91 | S100A4 (0.61) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL6817169 | 0.90 | MEN1 (0.55) | MEN1KMT2ATHRBBLMRECQL | |
| Idarubicin SCHEMBL17493323 | 0.90 | MEN1 (0.61) | MEN1KMT2ATHRBBLMRECQL | |
| Idarubicin SCHEMBL16827021 | 0.89 | ECE1 (0.62) | MEN1KMT2ATHRBBLMRECQL | |
| Valrubicin SCHEMBL2334615 | 0.85 | MEN1 (0.71) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL5984229 | 0.84 | MEN1 (0.56) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 0.81 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108785305-A | The heterocycle inhibitor of glutaminase | 卡利泰拉生物科技公司 | 2018-11-13 | — | — | CN | claimed |
| US-20160024216-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | CROWN BIOSCIENCE, INC. (TAICANG) (CN) | 2016-01-28 | — | — | US | claimed |
| WO-2014153018-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | CROWN BIOSCIENCE, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| WO-2014139131-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | CROWN BIOSCIENCE, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20240018224-A1 | ANTI-GPC3 ANTIBODY | YAMAGUCHI UNIVERSITY (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20230257705-A1 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING IMMUNOCOMPETENT CELLS | UNIV KYOTO (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11718663-B2 | Anti-GPC3 antibody | YAMAGUCHI UNIVERSITY (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-4170020-A1 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING IMMUNOCOMPETENT CELLS | Kyoto University (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-20230071098-A1 | ANTI-GPC3 SINGLE-CHAIN ANTIBODY-CONTAINING CAR | NOILE-IMMUNE BIOTECH, INC. (JP) | 2023-03-09 | — | — | US | disclosed |
| CN-111405895-B | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3597742-B1 | CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | UNIV YAMAGUCHI (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-20210309712-A1 | CAR-EXPRESSING T CELLS AND CAR EXPRESSION VECTOR | NOILE-IMMUNE BIOTECH, INC. (JP) | 2021-10-07 | — | — | US | disclosed |
| EP-3205720-B1 | CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | UNIV YAMAGUCHI (JP) | 2019-09-11 | — | — | EP | disclosed |
| US-10316102-B2 | Car expression vector and car-expressing T cells | YAMAGUCHI UNIVERSITY (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20170291953-A1 | CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | YAMAGUCHI UNIVERSITY (JP) | 2017-10-12 | — | — | US | disclosed |
| EP-3205720-A1 | CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS | Yamaguchi University (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20160024216-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | CROWN BIOSCIENCE, INC. (TAICANG) (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2014153018-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | CROWN BIOSCIENCE, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014139131-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | CROWN BIOSCIENCE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2005094824-A1 | METHODS OF ENHANCING CANCER THERAPY BY PROTECTING NERVE CELLS | EAST CAROLINA UNIVERSITY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024216-A1 | USE OF EGFR BIOMARKERS FOR THE TREATMENT OF GASTRIC CANCER WITH ANTI-EGFR AGENTS | EGFR, ERBB2, ERBB4 | TOP2A 4031/4885MEN1 4300/4885KMT2A 2393/4885 |
| US-11718663-B2 | Anti-GPC3 antibody | GOLGA3, CD99, GLG1 | TOP2A 4049/4885MEN1 3181/4885KMT2A 2729/4885 |
| US-20230071098-A1 | ANTI-GPC3 SINGLE-CHAIN ANTIBODY-CONTAINING CAR | IFNG, ICOS, STING1 | TOP2A 2768/4885MEN1 3445/4885KMT2A 4072/4885 |
| US-20240018224-A1 | ANTI-GPC3 ANTIBODY | GOLGA3, CD99, GLG1 | TOP2A 4049/4885MEN1 3181/4885KMT2A 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.